Endo Tries Its Luck With The Irish Through $1.6 Billion Paladin Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma will expand its global footprint, continue its re-transformation into a specialty pharma business, and gain an appealing new tax rate through the acquisition of Montreal-based Paladin Labs.
You may also be interested in...
Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.
Endo’s Next Chapter Will Be Led By CEO De Silva
Former Valeant President De Silva joins Endo in the midst of a challenging year for the company, as two top-selling drugs face generic competition. De Silva will need to reenergize Endo and do so quickly if he is to maintain the early favor he appears to have won from investors.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.